{
    "id": 22509,
    "fullName": "TNFRSF10B positive",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "TNFRSF10B positive indicates the presence of the TNFRSF10B gene, mRNA, and/or protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 8795,
        "geneSymbol": "TNFRSF10B",
        "terms": [
            "TNFRSF10B",
            "CD262",
            "DR5",
            "KILLER",
            "KILLER/DR5",
            "TRAIL-R2",
            "TRAILR2",
            "TRICK2",
            "TRICK2A",
            "TRICK2B",
            "TRICKB",
            "ZTNFR9"
        ]
    },
    "variant": "positive",
    "createDate": "05/12/2016",
    "updateDate": "01/02/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 14982,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GEN1029 demonstrated cytotoxicity towards patient-derived multiple myeloma cells, and the cell lysis level correlated with their Tnfrsf10b (Dr5) expression levels (Blood 2017 130(Suppl 1): 1835).",
            "molecularProfile": {
                "id": 23094,
                "profileName": "TNFRSF10B positive"
            },
            "therapy": {
                "id": 7299,
                "therapyName": "GEN1029",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11936,
                    "pubMedId": null,
                    "title": "Potent Ex Vivo Anti-Tumor Activity in Relapsed Refractory Multiple Myeloma Using Novel DR5-Specific Antibodies with Enhanced Capacity to Form Hexamers upon Target Binding",
                    "url": "http://www.bloodjournal.org/content/130/Suppl_1/1835?sso-checked=true"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14969,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, RO6874813 (RG7386) demonstrated safety and efficacy in patients with solid tumors positive for FAP and TNFRSF10B (DR5) (AACR; Mol Cancer Ther 2018;17(1 Suppl):Abstract nr A092, NCT02558140).",
            "molecularProfile": {
                "id": 23096,
                "profileName": "FAP pos TNFRSF10B pos"
            },
            "therapy": {
                "id": 4110,
                "therapyName": "RG7386",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11869,
                    "pubMedId": null,
                    "title": "Phase 1 trial of RO6874813, a novel bispecific FAP-DR5 antibody, in patients with solid tumors",
                    "url": "http://mct.aacrjournals.org/content/17/1_Supplement/A092"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6276,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TNFRSF10B and FAP positive breast cancer cells demonstrated sensitivity to RG7386, resulting in apoptotic induction in culture (PMID: 27037412).",
            "molecularProfile": {
                "id": 23096,
                "profileName": "FAP pos TNFRSF10B pos"
            },
            "therapy": {
                "id": 4110,
                "therapyName": "RG7386",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5521,
                    "pubMedId": 27037412,
                    "title": "RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27037412"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 23094,
            "profileName": "TNFRSF10B positive",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 23096,
            "profileName": "FAP pos TNFRSF10B pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28848,
            "profileName": "BCL2L1 pos TNFRSF10B pos",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}